Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech Signs CMO Deal with TaiMed Biologics

publication date: Aug 28, 2012
WuXi PharmaTech signed a contract manufacturing agreement with TaiMed Biologics of Taiwan to manufacture a mAb that was developed to treat HIV. WuXi will make ibalizumab (TMB-355) for the drug’s Phase II and Phase III global clinical trials. Ibalizumab is a viral-entry inhibitor that does not suppress the immune system. WuXi will complete the work at its biologics manufacturing facilities in China and its biologics testing facilities in the US. More details...

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

 

China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020

Other Events

CLINICAL DEVELOPMENT LEADERS' SUMMIT

Shanghai, China

November 12-14, 2019

 

CHINA HEALTHCARE SUMMIT 2019

Shanghai, China

November 18-20, 2019